Clinical Trial: NCT02981628
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Children's Oncology Group |
| Information Provided By: | Children's Oncology Group |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Official Title
Conditions
Intervention / Treatment
- Drug: Asparaginase Erwinia chrysanthemi
- Procedure: Biospecimen Collection
- Procedure: Bone Marrow Aspiration and Biopsy
- Drug: Calaspargase Pegol
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Procedure: Diagnostic Imaging Testing
- Biological: Inotuzumab Ozogamicin
- Drug: Leucovorin Calcium
- Procedure: Lumbar Puncture
- Drug: Methotrexate
- Drug: Pegaspargase
- Drug: Vincristine
Other Study ID Numbers
- AALL1621
- NCI-2016-01494
- AALL1621
- AALL1621
- U10CA180886
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Children's Oncology Group |
| Information Provided By: | Children's Oncology Group |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Official Title
Conditions
Intervention / Treatment
- Drug: Asparaginase Erwinia chrysanthemi
- Procedure: Biospecimen Collection
- Procedure: Bone Marrow Aspiration and Biopsy
- Drug: Calaspargase Pegol
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Procedure: Diagnostic Imaging Testing
- Biological: Inotuzumab Ozogamicin
- Drug: Leucovorin Calcium
- Procedure: Lumbar Puncture
- Drug: Methotrexate
- Drug: Pegaspargase
- Drug: Vincristine
Other Study ID Numbers
- AALL1621
- NCI-2016-01494
- AALL1621
- AALL1621
- U10CA180886